Long QT Syndrome Publications

Our Publications

  • “Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2,” Giannetti et al.

    EP Europace, 2023;, euad094, doi.org/10.1093/europace/euad094

    Access paper

  • “SGK1 Inhibition Attenuates the Action Potential Duration in Re-Engineered Heart Cell Models of Drug-Induced QT Prolongation,” Kim M, Sager PT et al.

    Heart Rhythm (2023), doi: https://doi.org/10.1016/ j.hrthm.2022.12.036

    Access paper

  • “SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome,” Kim M, Sager PT et al.

    Heart Rhythm February 15, 2023 DOI:https://doi.org/10.1016/j.hroo.2023.02.003

    Access Paper

Reference Publications

  • “Inhibition of serum & glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders,” Bezzerides et al.

    Sci Rep. 2017 Mar 23;7(1):346. doi: 10.1038/s41598-017-00413-3. PMID: 28336914; PMCID: PMC5428512

    Access paper

  • “Risk Stratification in the Long-QT Syndrome,” Priori et al.

    N Engl J Med. 2003 May 8;348(19):1866-74. doi: 10.1056/NEJMoa022147. PMID: 12736279

    Access paper

  • “Effectiveness & Limitations of β-Blocker Therapy in Congenital Long-QT Syndrome,” Moss et al.

    Circulation. 2000;101:616-623 doi: 10.1161/01.CIR.101.6.616

    Access paper

  • “Modulating Effects of Age and Gender on the Clinical Course of Long QT Syndrome by Genotype,” Zareba et al.

    JACC Vol. 42, No. 1, 2003 July 2, 2003:103–9 doi:10.1016/S0735-1097(03)00554-0

    Access paper

Atrial Fibrillation Publications

Our Publications

  • SGK1-I protects mice from obesity-related AF. These data further highlight SGK1 and its inhibition as a compelling target in cardiac arrhythmogenesis.

    Aneesh Bapat, Sabindra Pradhananga, Dinesh Srinivasan, Philip Sager and Patrick T Ellinor

    Originally published 6 Nov 2023 Circulation. 2023;148:A15963

    Access paper

Reference Publications

  • “Genetic inhibition of serum glucocorticoid kinase 1 prevents obesity-related atrial fibrillation,” Bapat…Das, Milan, et al.

    JCI Insight. 2022 Oct 10;7(19):e160885. doi: 10.1172/jci.insight. 160885. PMID: 35998035.

    Access paper

Oncology Publications

Reference Publications

  • “SGK1 is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance,” Arturo Orlacchio, Michela Ranieri, Martina Brave, et al.

    Cancer Res 2017;77:6914-6926. Published OnlineFirst October 20, 2017. DOI: 10.1158/0008-5472.CAN-17-2105

    Access paper

  • “PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Ka Inhibition.” Castel et al.

    Cancer Cell 30, 229–242 August 8, 2016 a 2016 The Author(s). Published by Elsevier Inc. DOI: 10.1016/j.ccell.2016.06.004

    Access paper

  • “Anaplastic thyroid cancer (ATC) is a rare and aggressive disease with 90% of patients succumbing to this disease 1 year after diagnosis. The approval of the combination therapy of a BRAF inhibitor dabrafenib with the MEK1/2 inhibitor trametinib has improved the overall survival of ATC patients. However, resistance to therapy remains a major problem”

    Madison M. Rose1 · Kelsey W. Nassar1 · Vibha Sharma1 · Rebecca E. Schweppe1

    Access Paper